IDYA News and Press, IDEAYA Biosciences Inc. From 09/26/23

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations PR Newswire Fast Track designation granted by U.S. FD...

2023-09-13 06:19:05 ET Summary IDEAYA Biosciences specializes in precision oncology, has FDA clearance for a Phase 1/2 trial, and partnerships with Amgen and GSK. Financially stable with a 50-month cash runway, the company has multiple clinical and preclinical programs in its dive...

IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors PR Newswire Initiated IDE161 Phase 1 expansion based on preliminary tumor shrinkage observed in multiple HRD solid tumor patients...

IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the dis...

2023-08-21 08:31:22 ET More on GSK, IDEAYA, etc. Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead GSK: A Muted Valuation And Good Dividend Yield GSK Stock: Optimistic After Solid Q2 Growth And Solidifying Guidance GSK Rating Upgraded To...

IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) PR Newswire GSK101 (IDE705) is being developed as a potential first-in-class Pol Theta Helicase Inhibitor in combination with niraparib in GSK-sponsored Phase...

IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma PR Newswire Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant the...

2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...

2023-08-11 15:41:02 ET Summary Ideaya Biosciences has made strong progress in the treatment of ocular cancer, with its stock price increasing over 150% since its IPO. The company's lead candidate, Darovasertib, has shown promising results in Phase 2 studies, with high response rat...

2023-08-10 10:54:17 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q2 GAAP EPS of -$0.50 beats by $0.06 . Revenue of $3.54M (-68.8% Y/Y) misses by $0.86M . Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of J...